Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 11,800 shares of the Company’s common stock, effective as of April 3, 2023. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company’s 2022 Inducement Plan, with a grant date of April 3, 2023, as an inducement material to the new employee entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).